EVIDENCE LIBRARY
Late-pregnancy clonazepam dispensing and child neurodevelopment: the exposure window matters
A multi-cohort study associated late-pregnancy clonazepam dispensing with neurodevelopmental diagnoses, while prescription and confounding limits remained.
A multi-cohort study associated late-pregnancy clonazepam dispensing with neurodevelopmental diagnoses, while prescription and confounding limits remained.
The defined exposure and outcome
The study combined five population-based child cohorts from Canada and the United States, totaling about 2.91 million children. Antiseizure medication exposure was defined by maternal prescription fills overlapping the 60 days before birth. Outcomes were identified through healthcare diagnosis algorithms.
Medication-specific analyses in the Canadian cohorts associated clonazepam exposure with a pooled adjusted hazard ratio of 1.22 for combined neurodevelopmental disorders, with a 95% confidence interval of 1.12–1.33. That estimate is a relative association, not a 22-percentage-point absolute increase.
What cannot be inferred about an individual child
Filled prescriptions do not prove consumption, and the study lacked dose-response analyses. Maternal indications and other differences may leave residual confounding despite adjustment. Children of treated mothers may also receive more developmental assessment, affecting diagnosis detection.
The result applies to a specified late-pregnancy window and combined outcome; it should not be silently extended to every trimester or every diagnosis. A clinical or legal assessment needs the actual treatment history and competing explanations. The paper does not establish individual causation or justify abrupt medication changes during pregnancy.
Source paper
Original analysis of the supplied journal article, identified as PMC12954148.